These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 37882731)
1. CD36 as a gatekeeper of myocardial lipid metabolism and therapeutic target for metabolic disease. Glatz JFC; Heather LC; Luiken JJFP Physiol Rev; 2024 Apr; 104(2):727-764. PubMed ID: 37882731 [TBL] [Abstract][Full Text] [Related]
2. CD36 (SR-B2) as master regulator of cellular fatty acid homeostasis. Glatz JFC; Nabben M; Luiken JJFP Curr Opin Lipidol; 2022 Apr; 33(2):103-111. PubMed ID: 35125400 [TBL] [Abstract][Full Text] [Related]
3. CD36 as a target for metabolic modulation therapy in cardiac disease. Glatz JFC; Wang F; Nabben M; Luiken JJFP Expert Opin Ther Targets; 2021 May; 25(5):393-400. PubMed ID: 34128755 [No Abstract] [Full Text] [Related]
4. Regulation of the subcellular trafficking of CD36, a major determinant of cardiac fatty acid utilization. Glatz JF; Nabben M; Heather LC; Bonen A; Luiken JJ Biochim Biophys Acta; 2016 Oct; 1861(10):1461-71. PubMed ID: 27090938 [TBL] [Abstract][Full Text] [Related]
5. Dynamic role of the transmembrane glycoprotein CD36 (SR-B2) in cellular fatty acid uptake and utilization. Glatz JFC; Luiken JJFP J Lipid Res; 2018 Jul; 59(7):1084-1093. PubMed ID: 29627764 [TBL] [Abstract][Full Text] [Related]
6. Understanding the distinct subcellular trafficking of CD36 and GLUT4 during the development of myocardial insulin resistance. Luiken JJFP; Nabben M; Neumann D; Glatz JFC Biochim Biophys Acta Mol Basis Dis; 2020 Jul; 1866(7):165775. PubMed ID: 32209364 [TBL] [Abstract][Full Text] [Related]
7. Specific amino acid supplementation rescues the heart from lipid overload-induced insulin resistance and contractile dysfunction by targeting the endosomal mTOR-v-ATPase axis. Wang S; Schianchi F; Neumann D; Wong LY; Sun A; van Nieuwenhoven FA; Zeegers MP; Strzelecka A; Col U; Glatz JFC; Nabben M; Luiken JJFP Mol Metab; 2021 Nov; 53():101293. PubMed ID: 34265467 [TBL] [Abstract][Full Text] [Related]
8. Palmitate-Induced Vacuolar-Type H Liu Y; Steinbusch LKM; Nabben M; Kapsokalyvas D; van Zandvoort M; Schönleitner P; Antoons G; Simons PJ; Coumans WA; Geomini A; Chanda D; Glatz JFC; Neumann D; Luiken JJFP Diabetes; 2017 Jun; 66(6):1521-1534. PubMed ID: 28302654 [TBL] [Abstract][Full Text] [Related]
9. Augmenting Vacuolar H Wang S; Wong LY; Neumann D; Liu Y; Sun A; Antoons G; Strzelecka A; Glatz JFC; Nabben M; Luiken JJFP Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102213 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of sarcolemmal FAT/CD36 by sulfo-N-succinimidyl oleate rapidly corrects metabolism and restores function in the diabetic heart following hypoxia/reoxygenation. Mansor LS; Sousa Fialho MDL; Yea G; Coumans WA; West JA; Kerr M; Carr CA; Luiken JJFP; Glatz JFC; Evans RD; Griffin JL; Tyler DJ; Clarke K; Heather LC Cardiovasc Res; 2017 Jun; 113(7):737-748. PubMed ID: 28419197 [TBL] [Abstract][Full Text] [Related]
11. Glycolysis-Mediated Activation of v-ATPase by Nicotinamide Mononucleotide Ameliorates Lipid-Induced Cardiomyopathy by Repressing the CD36-TLR4 Axis. Wang S; Han Y; Liu R; Hou M; Neumann D; Zhang J; Wang F; Li Y; Zhao X; Schianchi F; Dai C; Liu L; Nabben M; Glatz JFC; Wu X; Lu X; Li X; Luiken JJFP Circ Res; 2024 Mar; 134(5):505-525. PubMed ID: 38422177 [TBL] [Abstract][Full Text] [Related]
12. From fat to FAT (CD36/SR-B2): Understanding the regulation of cellular fatty acid uptake. Glatz JF; Luiken JJ Biochimie; 2017 May; 136():21-26. PubMed ID: 28013071 [TBL] [Abstract][Full Text] [Related]
14. Role of CD36 in membrane transport of long-chain fatty acids. Ibrahimi A; Abumrad NA Curr Opin Clin Nutr Metab Care; 2002 Mar; 5(2):139-45. PubMed ID: 11844979 [TBL] [Abstract][Full Text] [Related]
15. CD36 (SR-B2) as a Target to Treat Lipid Overload-Induced Cardiac Dysfunction. Glatz JFC; Luiken JJFP; Nabben M J Lipid Atheroscler; 2020 Jan; 9(1):66-78. PubMed ID: 32821722 [TBL] [Abstract][Full Text] [Related]
16. Prostaglandin E receptor subtype 4 protects against diabetic cardiomyopathy by modulating cardiac fatty acid metabolism via FOXO1/CD36 signalling. Ying F; Liu H; Ching Tang EH; Lakhani I; Liu N; Xia Z; Liu S Biochem Biophys Res Commun; 2021 Apr; 548():196-203. PubMed ID: 33647796 [TBL] [Abstract][Full Text] [Related]
17. Cardiac and skeletal muscle fatty acid transport and transporters and triacylglycerol and fatty acid oxidation in lean and Zucker diabetic fatty rats. Bonen A; Holloway GP; Tandon NN; Han XX; McFarlan J; Glatz JF; Luiken JJ Am J Physiol Regul Integr Comp Physiol; 2009 Oct; 297(4):R1202-12. PubMed ID: 19675275 [TBL] [Abstract][Full Text] [Related]
18. Chylomicron- and VLDL-derived lipids enter the heart through different pathways: in vivo evidence for receptor- and non-receptor-mediated fatty acid uptake. Bharadwaj KG; Hiyama Y; Hu Y; Huggins LA; Ramakrishnan R; Abumrad NA; Shulman GI; Blaner WS; Goldberg IJ J Biol Chem; 2010 Dec; 285(49):37976-86. PubMed ID: 20852327 [TBL] [Abstract][Full Text] [Related]
19. CD36 as a target to prevent cardiac lipotoxicity and insulin resistance. Glatz JF; Angin Y; Steinbusch LK; Schwenk RW; Luiken JJ Prostaglandins Leukot Essent Fatty Acids; 2013 Jan; 88(1):71-7. PubMed ID: 22580174 [TBL] [Abstract][Full Text] [Related]
20. Protein kinase-D1 and downstream signaling mechanisms involved in GLUT4 translocation in cardiac muscle. Simsek Papur O; Glatz JFC; Luiken JJFP Biochim Biophys Acta Mol Cell Res; 2024 Aug; 1871(6):119748. PubMed ID: 38723678 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]